Alnylam Pharmaceuticals (ALNY) Operating Leases (2019 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Operating Leases came in at $210.5 million in Q2 2026, down 6.22% YoY from $224.4 million in Q2 2025, and down 3.45% on a QoQ basis from $218.0 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Operating Leases (2019 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 8 years of Operating Leases data on file, last reported at $210.5 million in Q2 2026.
- Quarterly Operating Leases fell 6.22% year-over-year to $210.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $210.5 million (down 6.22% YoY) and the FY2025 annual result came in at $225.1 million, down 1.94% from the prior year.
- Operating Leases retreated to $210.5 million in Q2 2026, from $218.0 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $277.4 million in Q1 2022 to a low of $210.5 million in Q2 2026.
- A 5-year average of $241.9 million and a median of $238.6 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2024 — Operating Leases slipped 8.32% — and 2025, when it decreased 1.94%.
- Tracing ALNY's Operating Leases over 5 years: stood at $261.3 million in 2022, then fell by 6.98% to $243.1 million in 2023, then retreated by 5.58% to $229.5 million in 2024, then fell by 1.94% to $225.1 million in 2025, then retreated by 6.48% to $210.5 million in 2026.
- The last three Operating Leases figures came in at $210.5 million (Q2 2026), $218.0 million (Q1 2026), and $225.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 210.50 Mn |
| Mar 31, 2026 | 218.03 Mn |
| Dec 31, 2025 | 225.09 Mn |
| Sep 30, 2025 | 223.42 Mn |
| Jun 30, 2025 | 224.45 Mn |
| Mar 31, 2025 | 230.06 Mn |
| Dec 31, 2024 | 229.54 Mn |
| Sep 30, 2024 | 236.03 Mn |
| Jun 30, 2024 | 239.35 Mn |
| Mar 31, 2024 | 237.83 Mn |
| Dec 31, 2023 | 243.10 Mn |
| Sep 30, 2023 | 247.71 Mn |
| Jun 30, 2023 | 253.42 Mn |
| Mar 31, 2023 | 259.40 Mn |
| Dec 31, 2022 | 261.34 Mn |
| Sep 30, 2022 | 266.32 Mn |
| Jun 30, 2022 | 272.02 Mn |
| Mar 31, 2022 | 277.39 Mn |
| Dec 31, 2021 | 281.35 Mn |
| Sep 30, 2021 | 286.03 Mn |